@article{JTD23053,
author = {Ting Ye and Haiquan Chen},
title = {Adjuvant targeted therapy for resected NSCLC: to be or not to be?},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 26},
year = {2018},
keywords = {},
abstract = {Lung cancer, one of the most frequent malignant tumors in the world, is the main cause of cancer-related death nowadays (1). Radical surgery remains the cornerstone of treatment for early-stage non-small cell lung cancer (NSCLC). However, despite undergoing potentially curative surgery, patients with stage I, II, or IIIA NSCLC are at substantial risk for recurrence and death (2).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/23053}
}